A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of...
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF sub(165)
About this item
Full title
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF sub(165)
Author / Creator
Journal title
Proceedings of the National Academy of Sciences - PNAS, 2005-12, Vol.102 (52), p.18902-18907
Language
English
Formats
More information
Scope and Contents
Contents
Aptamers recognize their targets with extraordinary affinity and specificity. The aptamer-based therapeutic, Macugen, is derived from a modified 2'fluoro pyrimidine RNA inhibitor to vascular endothelial growth factor (VEGF) and is now being used to treat the wet form of age-related macular degeneration. This VEGF sub(165) aptamer binds specifically...
Alternative Titles
Full title
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF sub(165)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_19706625
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_19706625
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
How to access this item
Log in as a Library member
